❌

Normal view

Integrated spatial omics of metabolic reprogramming and the tumor microenvironment in pancreatic cancer

iScience. 2025 May 15;28(6):112681. doi: 10.1016/j.isci.2025.112681. eCollection 2025 Jun 20.

ABSTRACT

Metabolic reprogramming is a defining feature of pancreatic cancer, influencing tumor progression and the tumor microenvironment. By integrating single-cell transcriptomics, spatial transcriptomics, and spatial metabolomics, this study visualized the spatial co-localization of metabolites and gene expression within tumor samples, uncovering metabolic heterogeneity and intercellular interactions. Spatial transcriptomics identified distinct pathological regions, which were further characterized using single-cell transcriptomic data and pathologist annotations. Pseudotime trajectory analysis revealed metabolic shifts along the malignant progression, while single-cell Metabolism (scMetabolism) delineated metabolic differences between pathological regions, classifying them as hypermetabolic or hypometabolic. Notably, aberrant cell communication between cancer cells, macrophages, and fibroblasts was observed, with key receptor-ligand pairs significantly co-expressed in malignant regions and correlated with poor prognosis. Spatial metabolomics imaging identified signature metabolites, highlighting metabolic alterations in amino acid metabolism, polyamine metabolism, fatty acid synthesis, and phospholipid metabolism. This integrated analysis provides critical insights into pancreatic cancer metabolism, offering potential avenues for targeted therapeutic interventions.

PMID:40538442 | PMC:PMC12177182 | DOI:10.1016/j.isci.2025.112681

Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications

Cancer Treat Rev. 2025 Jun 14;139:102979. doi: 10.1016/j.ctrv.2025.102979. Online ahead of print.

ABSTRACT

Breast cancer is characterized by significant molecular heterogeneity; therefore, there are distinct clinical features, treatment modalities, and prognostic outcomes across its various molecular subtypes. In the era of precision medicine, liquid biopsy has emerged as a convenient and minimally invasive technique capable of dynamically representing the comprehensive tumor gene spectrum. This review systematically elaborates the clinical value of liquid biopsy as a breakthrough tool for precision diagnosis and treatment in breast cancer through dynamic detection of key biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and non-coding RNA (ncRNA). Specific genetic mutations and methylation signatures in ctDNA can be applied to early breast cancer screening, minimal residual disease monitoring, and tracking drug resistance mechanisms. CTCs enumeration (≥1/7.5 mL in early-stage cancer or ≥ 5/7.5 mL in metastatic cancer) and PD-L1 expression levels demonstrate direct correlations with prognostic stratification and the efficacy of immunotherapy. As the specificity and sensitivity of liquid biopsy continue to improve, personalized treatment strategies, informed by biomarker analysis and targeted precision therapies, have unveiled new avenues of hope for patients with breast cancer. However, several challenges persist in the practical application of liquid biopsy. Despite persistent challenges, such as insufficient standardization and difficulties in resolving low-abundance variants, future advancements should focus on multi-omics integration and AI-driven technological breakthroughs to overcome bottlenecks in clinical translation. This review summarizes cutting-edge liquid biopsy technologies for identifying clinically significant molecular biomarkers, focusing on discussing critical challenges in the strategies to advance precision oncology applications for optimized treatment guidance and disease surveillance in breast cancer.

PMID:40540857 | DOI:10.1016/j.ctrv.2025.102979

Exploring AI tools and multi-omics for precision medicine in lung cancer therapy

Cytokine Growth Factor Rev. 2025 Jun 6:S1359-6101(25)00071-1. doi: 10.1016/j.cytogfr.2025.06.001. Online ahead of print.

ABSTRACT

Lung cancer is a leading cause of cancer-related mortality worldwide, characterized by the uncontrolled growth and spread of abnormal cells. Despite constant progress in diagnosis and treatment of lung cancer remains highly challenging. Present review explores the molecular underpinnings of lung cancer, emphasizing genetic mutations, altered metabolism, and the role of biomarkers in diagnosis and treatment. Advances in diagnostic methods, particularly liquid biopsies, have enabled non-invasive detection and monitoring of lung cancer. Therapeutic approaches have evolved significantly, with molecular-targeted therapies focusing on pathways like EGFR, ALK, KRAS, and MET. Caner Immunotherapy, including immune checkpoint inhibitors, artificial intelligence, and multi-omics analysis, including genomics and image data to predict treatment response, has further enhanced precision medicine by enabling earlier detection, better prognostic models, and efficient drug discovery. AI has a significant impact on various aspects of oncology, including improving the earlier diagnosis of lung cancer. Despite these advancements, challenges such as drug resistance, tumor heterogeneity, and limited efficacy of certain therapies persist, necessitating continued research and innovation.

PMID:40544104 | DOI:10.1016/j.cytogfr.2025.06.001

FAAP100:A biomarker based on pan-cancer analysis, promotes the progression of lung adenocarcinoma

Cell Signal. 2025 Jun 18;134:111950. doi: 10.1016/j.cellsig.2025.111950. Online ahead of print.

ABSTRACT

FAAP100 plays an essential role in DNA damage repair, with dysregulation associated with elevated cancer susceptibility. Nevertheless, comprehensive pan-cancer analyses examining FAAP100 prognostic significance, immune correlations, and epigenetic regulation remains unexplored. This study systematically characterized FAAP100 across 33 cancer types utilizing multi-omics data from TCGA, UALCAN, cBioPortal, TIMER2.0, and CPTAC. Analytical assessments included expression profiles, prognostic significance, and diagnostic utility, alongside associations with DNA methylation, immune cell infiltration, immune checkpoint gene expression, tumor mutational load (TMB), microsatellite instability (MSI), and drug resistance. Findings revealed significant FAAP100 upregulation across multiple cancer types, exhibiting inverse correlations to patient survival. Genomic characterization identified associations between FAAP100 overexpression and both copy number amplification and promoter hypomethylation. Immune profiling demonstrated robust correlations with immune cell infiltration levels and checkpoint molecule activity. Functional assays utilizing PC9 and H1299 cells indicated that FAAP100 enhances cellular proliferation and migration while inhibiting apoptosis processes. In vivo studies confirmed tumor growth suppression upon FAAP100 knockdown. Collectively, this multi-omics investigation identifies FAAP100 as a pan-cancer oncogene driver, highlighting its potential as both a prognostic biomarker and therapeutic target. The integrated analysis of expression patterns, epigenetic modifications, immune characteristics, and genomic alterations elucidates the mechanistic involvement of FAAP100 in tumor progression, providing a foundation for clinical application in precision oncology approaches..

PMID:40541815 | DOI:10.1016/j.cellsig.2025.111950

Comprehensive Bibliometric Analysis of Prediction Models for HCC: Current Trends and Future Prospects

J Gastrointest Cancer. 2025 Jun 19;56(1):139. doi: 10.1007/s12029-025-01249-1.

ABSTRACT

BACKGROUND: Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor, with rising incidence and mortality rates posing a significant threat to global public health. Accurate prediction of liver cancer occurrence and progression is essential for improving patient prognosis. This study uses bibliometric methods to analyze the current state and future trends in liver cancer prediction research.

METHODS: A search was conducted in the Web of Science (WOS) database on October 22, 2023, identifying 1092 articles on liver cancer prediction. These articles were quantitatively analyzed using CiteSpace 6.2 software, with a focus on research hotspots, authors, countries, and keywords.

RESULTS: The study involved 114 countries, 4254 institutions, and 280 journals, with 48,788 citations. China (826 papers) and the USA (96 papers) dominate the field. Leading institutions include Sun Yat-sen University, Fudan University, Zhejiang University, and Yonsei University. The most cited journals were Hepatology (2209 citations) and Journal of Hepatology (946 citations). Frontiers in Oncology had the highest H-index (14). Key authors include Kim Seung Up (23 papers) and Ahn Sang Hoon (H-index = 14). Early research focused on risk factors and staging, while recent studies emphasize DNA methylation, immune microenvironments, and tumor metastasis. Future research will focus on multi-omics data integration and AI-driven predictive model optimization.

CONCLUSION: This study provides a comprehensive overview of liver cancer prediction research, highlighting key trends and the potential of multi-omics data and machine learning to enhance predictive models and clinical outcomes.

PMID:40537718 | DOI:10.1007/s12029-025-01249-1

AlphaWrite: Improving AI Narratives through Evolution

21 June 2025 at 19:34

AlphaWrite is a new framework designed to enhance creative writing with structure and measurable improvements. Developed by Toby Simonds, it employs an evolutionary process to iteratively boost storytelling quality during inference.

By Robert Krzaczyński

Biomarkers associated with cancer-related anorexia in lung cancer: a scoping review

Support Care Cancer. 2025 Jun 19;33(7):596. doi: 10.1007/s00520-025-09670-9.

ABSTRACT

PURPOSE: Anorexia is a frequent and serious symptom in patients with lung cancer, often leading to malnutrition and cachexia, and negatively affecting quality of life and survival. This scoping review systematically synthesizes current evidence on biomarkers associated with cancer-related anorexia (CRA) in lung cancer, aiming to clarify biological mechanisms and inform targeted interventions.

METHODS: We performed a comprehensive literature search of studies evaluating the associations between CRA and various biomarkers in patients with lung cancer. Data were extracted and analyzed for pathway, genomic, transcriptomic, epigenetic, proteomic, metabolic, and composite biomarkers.

RESULTS: A total of 33 studies were included, identifying more than 100 biomarkers closely associated with CRA in lung cancer. These include inflammatory cytokines, energy metabolism markers, epigenetic and transcriptomic alterations, and disruptions in multiple cellular signaling pathways. Our analysis demonstrates that CRA is not the result of a single factor but reflects widespread dysregulation across metabolic, immune, and signaling networks. Some studies suggest that nutritional and anti-inflammatory interventions, such as n-3 fatty acid and antioxidant supplementation, can modulate biomarker profiles and potentially improve clinical outcomes.

CONCLUSION: CRA in lung cancer is a multifactorial syndrome involving complex interactions among inflammatory, metabolic, and signaling pathways. Multi-omics biomarker integration holds promise for early detection and individualized treatment, but larger, multi-center studies are needed to confirm clinical utility and optimize management strategies. Precision interventions based on biomarker profiles should be further explored in future research and practice.

PMID:40536584 | DOI:10.1007/s00520-025-09670-9

MOLUNGN: a multi-omics graph neural network for biomarker discovery and accurate lung cancer classification

Front Genet. 2025 Jun 4;16:1610284. doi: 10.3389/fgene.2025.1610284. eCollection 2025.

ABSTRACT

INTRODUCTION: Lung cancer continues to pose significant global health burdens due to its high morbidity and mortality. This study aimed to systematically integrate biomedical datasets, particularly incorporating traditional Chinese medicine (TCM)-associated multi-omics data, employing advanced deep-learning methods enhanced by graph attention mechanisms. We sought to investigate molecular mechanisms underlying stage-wise lung cancer progression and identify pivotal stage-specific biomarkers to support precise cancer staging classification.

METHODS: We developed a novel multi-omics integrative model, named the Multi-Omics Lung Cancer Graph Network (MOLUNGN), based on Graph Attention Networks (GAT). Clinical datasets of non-small cell lung cancer (NSCLC), including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), were analyzed to create omics-specific feature matrices comprising mRNA expression, miRNA mutation profiles, and DNA methylation data. MOLUNGN incorporated omics-specific GAT modules (OSGAT) combined with a Multi-Omics View Correlation Discovery Network (MOVCDN), effectively capturing intra- and inter-omics correlations. This framework enabled comprehensive classification of clinical cases into precise cancer stages, alongside the extraction of stage-specific biomarkers.

RESULTS: Evaluations utilizing publicly available datasets confirmed MOLUNGN's superior performance over existing methodologies. On the LUAD dataset, MOLUNGN achieved accuracy (ACC) of 0.84, Recall_weighted of 0.84, F1_weighted of 0.83, and F1_macro of 0.82. On the LUSC dataset, the model further improved, achieving ACC of 0.86, Recall_weighted of 0.86, F1_weighted of 0.85, and F1_macro of 0.84. Notably, critical stage-specific biomarkers with significant biological relevance to lung cancer progression were identified, facilitating robust gene-disease associations.

DISCUSSION: Our findings underscore the efficacy of MOLUNGN as an integrative framework in accurately classifying lung cancer stages and uncovering essential biomarkers. These biomarkers provide deep insights into lung cancer progression mechanisms and represent promising targets for future clinical validation. Integrating these biomarkers into the TCM-target-disease network enriches the understanding of TCM therapeutic potentials, laying a robust foundation for future precision medicine applications.

PMID:40534839 | PMC:PMC12174459 | DOI:10.3389/fgene.2025.1610284

  • ✇MIT Technology Review
  • The Download: tackling tech-facilitated abuse, and opening up AI hardware Charlotte Jee
    This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Why it’s so hard to stop tech-facilitated abuse After Gioia had her first child with her then husband, he installed baby monitors throughout their home—to “watch what we were doing,” she says, while he went to work. She’d turn them off; he’d get angry. By the time their third child turned seven, Gioia and her husband had divorced, but he still found ways
     

The Download: tackling tech-facilitated abuse, and opening up AI hardware

18 June 2025 at 20:15

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.

Why it’s so hard to stop tech-facilitated abuse

After Gioia had her first child with her then husband, he installed baby monitors throughout their home—to “watch what we were doing,” she says, while he went to work. She’d turn them off; he’d get angry. By the time their third child turned seven, Gioia and her husband had divorced, but he still found ways to monitor her behavior. One Christmas, he gave their youngest a smartwatch. Gioia showed it to a tech-savvy friend, who found that the watch had a tracking feature turned on. It could be turned off only by the watch’s owner—her ex.

And Gioia is far from alone. In fact, tech-facilitated abuse now occurs in most cases of intimate partner violence—and we’re doing shockingly little to prevent it. Read the full story. 

—Jessica Klein 

This story is from the next print edition of MIT Technology Review, which explores power—who has it, and who wants it. It’s set to go live on Wednesday June 25, so subscribe & save 25% to read it and get a copy of the issue when it lands!

Why AI hardware needs to be open

—by Ayah Bdeir, a leader in the maker movement, champion of open source AI, and founder of littleBits, the hardware platform that teaches STEAM to kids through hands-on invention. 

Once again, the future of technology is being engineered in secret by a handful of people and delivered to the rest of us as a sealed, seamless, perfect device. When technology is designed like this, we are reduced to consumers. We don’t shape the tools; they shape us. 

However, this moment creates a chance to do things differently. Because away from the self-centeredness of Silicon Valley, a quiet, grounded sense of resistance is reactivating.  Read the full story.

MIT Technology Review Narrated: Deepfakes of your dead loved ones are a booming Chinese business

In China, people are seeking help from AI-generated avatars to process their grief after a family member passes away. Our story about this trend is the latest to be turned into a MIT Technology Review Narrated podcast, which we’re publishing each week on Spotify and Apple Podcasts. Just navigate to MIT Technology Review Narrated on either platform, and follow us to get all our new content as it’s released.

The must-reads

I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.

1 Iran is going offline to avoid Israeli cyberattacks
A government spokesperson said it plans to disconnect completely from the global internet this evening. (The Verge)
+ How attacks on Iran’s oil exports could hurt China. (WSJ $)

2 Trump is giving TikTok another reprieve from a US ban
It’s been a full five years since he signed the original executive order telling Bytedance to sell it. (CNN)
+ Why Chinese manufacturers are going viral on TikTok. (MIT Technology Review)

3 Conspiracy theories about the Minnesota shooting are all over social media
Whenever there’s an information vacuum, people are all too keen to fill it with noise and nonsense. (NBC) 
+ The shooting suspect allegedly used data broker sites to find targets’ addresses. (Wired $)

4 Tensions between OpenAI and Microsoft are starting to boil over 
OpenAI has even threatened to report its formerly close partner to antitrust regulators. (WSJ $)
+ Here are the concessions OpenAI is seeking. (The Information $)
+ Inside the story that enraged OpenAI. (MIT Technology Review) 

5 California cops are using AI cameras to investigate ICE protests
And sharing license plate data with other agencies, a practice some experts say is illegal. (404 Media)
+ How a new type of AI is helping police skirt facial recognition bans. (MIT Technology Review)

6 Social media is now Americans’ primary news source
It’s overtaken TV for the first time. (Reuters)
+ They watched more TV via streaming than cable last month, too. (NYT $)

7 Weight loss drugs may not work quite as well as hoped
Researchers analysed data from 51,085 patients and found bariatric surgery delivered better, more sustainable results. (The Guardian)

8 What is AI doing to reading? 📖
Here’s what we stand to gain—and lose—when we outsource reading to machines. (New Yorker $) 

9 India is relying on China to build up its EV market
It’s taking a drastically different course to the US. (Rest of World)
+ Why EVs are (mostly) set for solid growth in 2025. (MIT Technology Review)

10 People are building AI tools to decipher cats’ meows 😸
Bet at least half of them are “feed me.” (Scientific American $)

Quote of the day

“Have we fallen so low? Have we no shame?”

—Remarks made by federal judge Williams G. Young this week as he voided some of the Trump administration’s cuts to National Institutes of Health grants, saying they were discriminatory, the New York Times reports. 

One more thing

a pixelated plate with the crusts of a sandwich and two pickle slices
STEPHANIE ARNETT/MIT TECHNOLOGY REVIEW | GETTY


Why AI could eat quantum computing’s lunch

Tech companies have been funneling billions of dollars into quantum computers for years. The hope is that they’ll be a game changer for fields as diverse as finance, drug discovery, and logistics.

But while the field struggles with the realities of tricky quantum hardware, another challenger is making headway in some of these most promising use cases. AI is now being applied to fundamental physics, chemistry, and materials science in a way that suggests quantum computing’s purported home turf might not be so safe after all. Read the full story.

—Edd Gent

We can still have nice things

A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line or skeet ’em at me.)

+ Wait a minute, Will Smith was offered a role in Inception? Much to think about.
+ No pain, no gain? Not necessarily.
+ John Waters, you really are one of a kind.
+ Say it ain’t so—I refuse to believe that young love is dead!

  • ✇MIT Technology Review
  • Why AI hardware needs to be open Ayah Bdeir
    When OpenAI acquired Io to create “the coolest piece of tech that the world will have ever seen,” it confirmed what industry experts have long been saying: Hardware is the new frontier for AI. AI will no longer just be an abstract thing in the cloud far away. It’s coming for our homes, our rooms, our beds, our bodies.  That should worry us. Once again, the future of technology is being engineered in secret by a handful of people and delivered to the rest of us as a sealed, seamless, perfec
     

Why AI hardware needs to be open

18 June 2025 at 16:49

When OpenAI acquired Io to create “the coolest piece of tech that the world will have ever seen,” it confirmed what industry experts have long been saying: Hardware is the new frontier for AI. AI will no longer just be an abstract thing in the cloud far away. It’s coming for our homes, our rooms, our beds, our bodies. 

That should worry us.

Once again, the future of technology is being engineered in secret by a handful of people and delivered to the rest of us as a sealed, seamless, perfect device. When technology is designed in secrecy and sold to us as a black box, we are reduced to consumers. We wait for updates. We adapt to features. We don’t shape the tools; they shape us. 

This is a problem. And not just for tinkerers and technologists, but for all of us.

We are living through a crisis of disempowerment. Children are more anxious than ever; the former US surgeon general described a loneliness epidemic; people are increasingly worried about AI eroding education. The beautiful devices we use have been correlated with many of these trends. Now AI—arguably the most powerful technology of our era—is moving off the screen and into physical space. 

The timing is not a coincidence. Hardware is having a renaissance. Every major tech company is investing in physical interfaces for AI. Startups are raising capital to build robots, glasses, wearables that are going to track our every move. The form factor of AI is the next battlefield. Do we really want our future mediated entirely through interfaces we can’t open, code we can’t see, and decisions we can’t influence? 

This moment creates an existential opening, a chance to do things differently. Because away from the self-centeredness of Silicon Valley, a quiet, grounded sense of resistance is reactivating. I’m calling it the revenge of the makers. 

In 2007, as the iPhone emerged, the maker movement was taking shape. This subculture advocates for learning-through-making in social environments like hackerspaces and libraries. DIY and open hardware enthusiasts gathered in person at Maker Faires—large events where people of all ages tinkered and shared their inventions in 3D printing, robotics, electronics, and more. Motivated by fun, self-fulfillment, and shared learning, the movement birthed companies like MakerBot, Raspberry Pi, Arduino, and (my own education startup) littleBits from garages and kitchen tables. I myself wanted to challenge the notion that technology had to be intimidating or inaccessible, creating modular electronic building blocks designed to put the power of invention in the hands of everyone.

By definition, the maker movement is humble and it is consistent. Makers do not believe in the cult of individual genius; we believe in collective genius. We believe that creativity is universally distributed (not exclusively bestowed), that inventing is better together, and that we should make open products so people can observe, learn, and create—basically, the polar opposite of what Jony Ive and Sam Altman are building.

But over time, the momentum faded. The movement was dismissed by the tech and investment industry as niche and hobbyist, and starting in 2018, pressures on the hardware venture market (followed by covid) made people retreat from social spaces to spend more time behind screens. 

Now it’s mounting a powerful second act, joined by a wave of AI open-source enthusiasts. This time around the stakes are higher, and we need to give it the support it never had.

In 2024 the AI leader Hugging Face developed an open-source platform for AI robots, which already has 3,500+ robot data sets and draws thousands of participants from every continent to join giant hackathons. Raspberry Pi went public on the London Stock Exchange for $700 million. After a hiatus, Maker Faire came back; the most recent one had nearly 30,000 attendees, with kinetic sculptures, flaming octopuses, and DIY robot bands, and this year there will be over 100 Maker Faires around the world. Just last week, DIY.org relaunched its app. In March, my friend Roya Mahboob, founder of the Afghan Girls Robotics Team, released a movie about the team to incredible reviews. People love the idea that making is the ultimate form of human empowerment and expression. All the while, a core set of people have continued influencing millions through maker organizations like FabLabs and Adafruit.

Studies show that hands-on creativity reduces anxiety, combats loneliness, and boosts cognitive function. The act of making grounds us, connects us to others, and reminds us that we are capable of shaping the world with our own hands. 

I’m not proposing to reject AI hardware but to reject the idea that innovation must be proprietary, elite, and closed. I’m proposing to fund and build the open alternative. That means putting our investment, time, and purchases towards robot built in community labs, AI models trained in the open, tools made transparent and hackable. That world isn’t just more inclusive—it’s more innovative. It’s also more fun. 

This is not nostalgia. This is about fighting for the kind of future we want: A future of openness and joy, not of conformity and consumption. One where technology invites participation, not passivity. Where children grow up not just knowing how to swipe, but how to build. Where creativity is a shared endeavor, not the mythical province of lone geniuses in glass towers.

In his Io announcement video, Altman said, “We are literally on the brink of a new generation of technology that can make us our better selves.” It reminded me of the movie Mountainhead, where four tech moguls tell themselves they are saving the world while the world is burning. I don’t think the iPhone made us our better selves. In fact, you’ve never seen me run faster than when I’m trying to snatch an iPhone out of my three-year-old’s hands.

So yes, I’m watching what Sam Altman and Jony Ive will unveil. But I’m far more excited by what’s happening in basements, in classrooms, on workbenches. Because the real iPhone moment isn’t a new product we wait for. It’s the moment you realize you can build it yourself. And best of all? You  can’t doomscroll when you’re holding a soldering iron.

Ayah Bdeir is a leader in the maker movement, a champion of open source AI, and founder of littleBits, the hardware platform that teaches STEAM to kids through hands-on invention. A graduate of the MIT Media Lab, she was selected as one of the BBC’s 100 Most Influential Women, and her inventions have been acquired by the Museum of Modern Art.

Deep learning and inflammatory markers predict early response to immunotherapy in unresectable NSCLC: A multicenter study

Biomol Biomed. 2025 Jun 10. doi: 10.17305/bb.2025.12324. Online ahead of print.

ABSTRACT

Immune checkpoint inhibitors (ICIs) demonstrate substantial interpatient variability in clinical efficacy for unresectable non-small cell lung cancer (NSCLC), underscoring the unmet need for noninvasive biomarkers to predict early therapeutic responses and improve survival outcomes. To address this, we developed a CT-based deep learning model integrated with the systemic immune-inflammatory-nutritional index (SIINI) for early prediction of ICI response. In a retrospective multicenter study of 265 patients treated with ICIs (incorporating chest CT and laboratory data), the cohort was divided into training (70%), internal validation (30%), and external validation sets. The combined model-leveraging DenseNet121-derived deep radiomic features alongside SIINI-achieved strong predictive performance, with AUCs of 0.865 (95% CI: 0.7709-0.9595) in the internal validation cohort and 0.823 (95% CI: 0.6627-0.9827) in the external validation cohort. Gradient-weighted class activation mapping (Grad-CAM) highlighted key CT regions contributing to model predictions, enhancing interpretability for clinical application. These findings highlight the potential of integrating deep learning with inflammatory biomarkers to support personalized ICI therapy in unresectable NSCLC. Future directions include incorporating multi-omics biomarkers, expanding multicenter validation, and increasing sample sizes to further improve predictive accuracy and facilitate clinical translation.

PMID:40525631 | DOI:10.17305/bb.2025.12324

  • ✇MIT Technology Review
  • AI copyright anxiety will hold back creativity Nitin Nohria
    Last fall, while attending a board meeting in Amsterdam, I had a few free hours and made an impromptu visit to the Van Gogh Museum. I often steal time for visits like this—a perk of global business travel for which I am grateful. Wandering the galleries, I found myself before The Courtesan (after Eisen), painted in 1887. Van Gogh had based it on a Japanese woodblock print by Keisai Eisen, which he encountered in the magazine Paris Illustré. He explicitly copied and reinterpreted Eisen’s composit
     

AI copyright anxiety will hold back creativity

17 June 2025 at 18:00

Last fall, while attending a board meeting in Amsterdam, I had a few free hours and made an impromptu visit to the Van Gogh Museum. I often steal time for visits like this—a perk of global business travel for which I am grateful. Wandering the galleries, I found myself before The Courtesan (after Eisen), painted in 1887. Van Gogh had based it on a Japanese woodblock print by Keisai Eisen, which he encountered in the magazine Paris Illustré. He explicitly copied and reinterpreted Eisen’s composition, adding his own vivid border of frogs, cranes, and bamboo.

As I stood there, I imagined the painting as the product of a generative AI model prompted with the query How would van Gogh reinterpret a Japanese woodblock in the style of Keisai Eisen? And I wondered: If van Gogh had used such an AI tool to stimulate his imagination, would Eisen—or his heirs—have had a strong legal claim?  If van Gogh were working today, that might be the case. Two years ago, the US Supreme Court found that Andy Warhol had infringed upon the photographer Lynn Goldsmith’s copyright by using her photo of the musician Prince for a series of silkscreens. The court said the works were not sufficiently transformative to constitute fair use—a provision in the law that allows for others to make limited use of copyrighted material.

A few months later, at the Museum of Fine Arts in Boston, I visited a Salvador Dalí exhibition. I had always thought of Dalí as a true original genius who conjured surreal visions out of thin air. But the show included several Dutch engravings, including Pieter Bruegel the Elder’s Seven Deadly Sins (1558), that clearly influenced Dalí’s 8 Mortal Sins Suite (1966). The stylistic differences are significant, but the lineage is undeniable. Dalí himself cited Bruegel as a surrealist forerunner, someone who tapped into the same dream logic and bizarre forms that Dalí celebrated. Suddenly, I was seeing Dalí not just as an original but also as a reinterpreter. Should Bruegel have been flattered that Dalí built on his work—or should he have sued him for making it so “grotesque”?

During a later visit to a Picasso exhibit in Milan, I came across a famous informational diagram by the art historian Alfred Barr, mapping how modernist movements like Cubism evolved from earlier artistic traditions. Picasso is often held up as one of modern art’s most original and influential figures, but Barr’s chart made plain the many artists he drew from—Goya, El Greco, Cézanne, African sculptors. This made me wonder: If a generative AI model had been fed all those inputs, might it have produced Cubism? Could it have generated the next great artistic “breakthrough”?

These experiences—spread across three cities and centered on three iconic artists—coalesced into a broader reflection I’d already begun. I had recently spoken with Daniel Ek, the founder of Spotify, about how restrictive copyright laws are in music. Song arrangements and lyrics enjoy longer protection than many pharmaceutical patents. Ek sits at the leading edge of this debate, and he observed that generative AI already produces an astonishing range of music. Some of it is good. Much of it is terrible. But nearly all of it borrows from the patterns and structures of existing work.

Musicians already routinely sue one another for borrowing from previous works. How will the law adapt to a form of artistry that’s driven by prompts and precedent, built entirely on a corpus of existing material?

And the questions don’t stop there. Who, exactly, owns the outputs of a generative model? The user who crafted the prompt? The developer who built the model? The artists whose works were ingested to train it? Will the social forces that shape artistic standing—critics, curators, tastemakers—still hold sway? Or will a new, AI-era hierarchy emerge? If every artist has always borrowed from others, is AI’s generative recombination really so different? And in such a litigious culture, how long can copyright law hold its current form? The US Copyright Office has begun to tackle the thorny issues of ownership and says that generative outputs can be copyrighted if they are sufficiently human-authored. But it is playing catch-up in a rapidly evolving field. 

Different industries are responding in different ways. The Academy of Motion Picture Arts and Sciences recently announced that filmmakers’ use of generative AI would not disqualify them from Oscar contention—and that they wouldn’t be required to disclose when they’d used the technology. Several acclaimed films, including Oscar winner The Brutalist, incorporated AI into their production processes.

The music world, meanwhile, continues to wrestle with its definitions of originality. Consider the recent lawsuit against Ed Sheeran. In 2016, he was sued by the heirs of Ed Townsend, co-writer of Marvin Gaye’s “Let’s Get It On,” who claimed that Sheeran’s “Thinking Out Loud” copied the earlier song’s melody, harmony, and rhythm. When the case finally went to trial in 2023, Sheeran brought a guitar to the stand. He played the disputed four-chord progression—I–iii–IV–V—and wove together a mash-up of songs built on the same foundation. The point was clear: These are the elemental units of songwriting. After a brief deliberation, the jury found Sheeran not liable.

Reflecting after the trial, Sheeran said: “These chords are common building blocks … No one owns them or the way they’re played, in the same way no one owns the colour blue.”

Exactly. Whether it’s expressed with a guitar, a paintbrush, or a generative algorithm, creativity has always been built on what came before.

I don’t consider this essay to be great art. But I should be transparent: I relied extensively on ChatGPT while drafting it. I began with a rough outline, notes typed on my phone in museum galleries, and transcripts from conversations with colleagues. I uploaded older writing samples to give the model a sense of my voice. Then I used the tool to shape a draft, which I revised repeatedly—by hand and with help from an editor—over several weeks.

There may still be phrases or sentences in here that came directly from the model. But I’ve iterated so much that I no longer know which ones. Nor, I suspect, could any reader—or any AI detector. (In fact, Grammarly found that 0% of this text appeared to be AI-generated.)

Many people today remain uneasy about using these tools. They worry it’s cheating, or feel embarrassed to admit that they’ve sought such help. I’ve moved past that. I assume all my students at Harvard Business School are using AI. I assume most academic research begins with literature scanned and synthesized by these models. And I assume that many of the essays I now read in leading publications were shaped, at least in part, by generative tools.

Why? Because we are professionals. And professionals adopt efficiency tools early. Generative AI joins a long lineage that includes the word processor, the search engine, and editing tools like Grammarly. The question is no longer Who’s using AI? but Why wouldn’t you?

I recognize the counterargument, notably put forward by Nicholas Thompson, CEO of the Atlantic: that content produced with AI assistance should not be eligible for copyright protection, because it blurs the boundaries of authorship. I understand the instinct. AI recombines vast corpora of preexisting work, and the results can feel derivative or machine-like.

But when I reflect on the history of creativity—van Gogh reworking Eisen, Dalí channeling Bruegel, Sheeran defending common musical DNA—I’m reminded that recombination has always been central to creation. The economist Joseph Schumpeter famously wrote that innovation is less about invention than “the novel reassembly of existing ideas.” If we tried to trace and assign ownership to every prior influence, we’d grind creativity to a halt.

From the outset, I knew the tools had transformative potential. What I underestimated was how quickly they would become ubiquitous across industries and in my own daily work.

Our copyright system has never required total originality. It demands meaningful human input. That standard should apply in the age of AI as well. When people thoughtfully engage with these models—choosing prompts, curating inputs, shaping the results—they are creating. The medium has changed, but the impulse remains the same: to build something new from the materials we inherit.


Nitin Nohria is the George F. Baker Jr. Professor at Harvard Business School and its former dean. He is also the chair of Thrive Capital, an early investor in several prominent AI firms, including OpenAI.

MIT Technology Review’s editorial guidelines state that generative AI should not be used to draft articles unless the article is meant to illustrate the capabilities of such tools and its use is clearly disclosed. 

Next-generation cancer therapeutics: unveiling the potential of liposome-based nanoparticles through bioinformatics

Mikrochim Acta. 2025 Jun 16;192(7):428. doi: 10.1007/s00604-025-07286-8.

ABSTRACT

Cancer remains one of the most deadly diseases in the world, requiring constant growth and improvements in therapeutic strategies. Traditional cancer treatments, such as chemotherapy, radiotherapy, and surgery, have limitations like off-target release, toxicity, and inefficient drug delivery. This study explains the role of bioinformatics and AI in optimizing and analyzing liposomal formulations for innovative and better cancer therapy. Molecular docking (MD), molecular dynamics simulations, and machine learning models are the computational techniques that can help to design stable liposomal carriers for drugs, predict receptor-ligand interactions, and can improve drug release efficiency. Improved liposome nanoparticles (LNPs) surface functionalization, the discovery of tumor-specific biomarkers, and the improvement of receptor-ligand interactions for accurate drug targeting are all made possible by bioinformatics tools and methodologies. Moreover, AI-assisted predictions and in silico modeling can speed up drug discovery and processing while eliminating the experimental expenditures and time. In the present review, we conducted MD studies to complement the discussed literature. MD was performed between cyclic RGD peptides (liposomal ligands) and the GPR116 receptor in triple-negative breast cancer, and between folic acid (liposomal ligand) and the Axl tyrosine kinase receptor for lung cancer, revealing strong and stable interactions and highlighting the amino acid residues involved. Notwithstanding current obstacles, computational tools have shown notable progress in nanomedicine, exploring more options for more individualized and effective cancer therapies. The combination of AI, machine learning, and multi-omics techniques to improve therapeutic efficacy and reduce side effects is a substantial key to the future of LNP-based cancer treatment.

PMID:40523994 | DOI:10.1007/s00604-025-07286-8

❌